Compare Medpace Holdings Inc (MEDP) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs WD 40 Company — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while WD 40 Company trades at $202.29 (market cap $2.73B). The key difference: Medpace Holdings Inc is far larger — about 6.2× WD 40 Company's market cap, and WD 40 Company pays a 2% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and WD 40 Company for 22 Days on average.
| MEDP | WDFC | |
|---|---|---|
Market Cap | $16.82B | $2.73B |
Volume | 223,093 | 130,665 |
Sector | Health | Basic Materials |
52-Week High | $630.19 | $264.91 |
52-Week Low | $393.42 | $187.52 |
Typical Hold Time | 14 Days | 22 Days |
Enterprise Value | $16.44B | $2.79B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
WDFC trades at $202.29, showing modest daily gains. The technical outlook is bullish, supported by moving averages, while recent earnings have largely beaten expectations. The company maintains strong profitability with a 13.22% net income margin and a 33.22% ROE, though valuation multiples like a P/E of 30.96 appear elevated. Positive news highlights strategic growth initiatives and institutional buying interest.
The stock presents a mixed outlook; robust fundamentals and growth strategy support upside, but high valuation and margin pressures from input costs pose risks. Analyst consensus is cautious with a majority hold rating, indicating balanced but not aggressive investor sentiment near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
